Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

PURPOSE: We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)– amplified human xenografts in mice by inhibition of the HER2 pathway with lapatinib and trastuzumab to block all homo- and heterodimer signaling as well as by blockade of estrogen receptor (ER) when e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Rimawi, Mothaffar F., Mayer, Ingrid A., Forero, Andres, Nanda, Rita, Goetz, Matthew P., Rodriguez, Angel A., Pavlick, Anne C., Wang, Tao, Hilsenbeck, Susan G., Gutierrez, Carolina, Schiff, Rachel, Osborne, C. Kent, Chang, Jenny C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2013
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3641695/
https://ncbi.nlm.nih.gov/pubmed/23569315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.44.8027
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge